THE DEAL, AT A GLANCE
From the announcementNovaGo Therapeutics
01What happenedNovaGo Therapeutics raised $30M Series B, announced 2026-09-01From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Why it mattersNovaGo Therapeutics represents a below-median Healthcare & Life Sciences Series B allocation directed toward a defined proof-of-concept study in acute spinal cord injury.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
NovaGo Therapeutics · Financing Record
Explore source-linked visual explanations for NovaGo Therapeutics. Unsupported claims are withheld while source review continues.
Record 11483 · Recorded date: 2026-09-01
Explore company records →